204 related articles for article (PubMed ID: 23167339)
1. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis.
Gu YH; Du JX; Ma ML
Asian Pac J Cancer Prev; 2012; 13(9):4335-9. PubMed ID: 23167339
[TBL] [Abstract][Full Text] [Related]
2. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
3. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations.
Zavos G; Karidis NP; Tsourouflis G; Bokos J; Diles K; Sotirchos G; Theodoropoulou E; Kostakis A
Int J Dermatol; 2011 Dec; 50(12):1496-500. PubMed ID: 21790552
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
[TBL] [Abstract][Full Text] [Related]
5. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
Campbell SB; Walker R; Tai SS; Jiang Q; Russ GR
Am J Transplant; 2012 May; 12(5):1146-56. PubMed ID: 22420843
[TBL] [Abstract][Full Text] [Related]
7. Management of non-melanoma skin cancer in solid organ transplant recipients.
Specchio F; Saraceno R; Chimenti S; Nistico S
Int J Immunopathol Pharmacol; 2014; 27(1):21-4. PubMed ID: 24674675
[TBL] [Abstract][Full Text] [Related]
8. [Risk factors of non melanoma skin cancers in kidney transplant patients].
Sułowicz J; Wojas-Pelc A; Ignacak E; Betkowska-Prokop A; Kuzniewski M; Sułowicz W
Przegl Lek; 2014; 71(1):19-25. PubMed ID: 24712264
[TBL] [Abstract][Full Text] [Related]
9. Interventions for preventing non-melanoma skin cancers in high-risk groups.
Bath-Hextall F; Leonardi-Bee J; Somchand N; Webster A; Delitt J; Perkins W
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005414. PubMed ID: 17943854
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
12. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
13. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.
Salgo R; Gossmann J; Schöfer H; Kachel HG; Kuck J; Geiger H; Kaufmann R; Scheuermann EH
Am J Transplant; 2010 Jun; 10(6):1385-93. PubMed ID: 20121752
[TBL] [Abstract][Full Text] [Related]
14. [Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].
Rodríguez-Acosta ED; Calva-Mercado JJ; Alberú-Gómez J; Vilatoba-Chapa M; Domínguez-Cherit J
Gac Med Mex; 2015; 151(1):20-6. PubMed ID: 25739480
[TBL] [Abstract][Full Text] [Related]
15. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.
Burke MT; Morais C; Oliver KA; Lambie DL; Gobe GC; Carroll RP; Staatz CE; Sinnya S; Soyer HP; Winterford C; Haass NK; Campbell SB; Isbel NM
Am J Clin Pathol; 2015 Apr; 143(4):514-26. PubMed ID: 25780003
[TBL] [Abstract][Full Text] [Related]
16. Overview on non-melanoma skin cancers in solid organ transplant recipients.
Forchetti G; Suppa M; Del Marmol V
G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224
[TBL] [Abstract][Full Text] [Related]
17. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients.
Kaufmann RA; Oberholzer PA; Cazzaniga S; Hunger RE
Eur J Dermatol; 2016 Jun; 26(3):265-70. PubMed ID: 26985913
[TBL] [Abstract][Full Text] [Related]
18. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
[TBL] [Abstract][Full Text] [Related]
19. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management.
Tessari G; Girolomoni G
Dermatol Surg; 2012 Oct; 38(10):1622-30. PubMed ID: 22805312
[TBL] [Abstract][Full Text] [Related]
20. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
